Related Experiment Video
Updated: Feb 8, 2026

Isolation of the Side Population in Myc-induced T-cell Acute Lymphoblastic Leukemia in Zebrafish
Published on: May 4, 2017
Fosphenytoin Population Pharmacokinetics in the Acutely Ill Pediatric Population
Brady S Moffett1,2, Mindl M Weingarten1,2, Lindsay R Schmees1,2
1Department of Pharmacy, Texas Children's Hospital, Houston, TX.
Insights
A loading dose of 20 mg/kg followed by 6 mg/kg every 8 hours is recommended for phenytoin (fosphenytoin) in pediatric patients. Dose adjustments are necessary for reduced kidney function and phenobarbital use impacts clearance.
Area of Science:
- Pharmacokinetics
- Pediatric Pharmacology
- Clinical Pharmacy
Background:
- Phenytoin is a critical anti-seizure medication.
- Optimizing phenytoin dosing in pediatric patients is essential for effective seizure control.
- Fosphenytoin offers an improved safety profile for intravenous phenytoin administration.
Purpose of the Study:
- To characterize the pharmacokinetics of phenytoin in pediatric patients receiving fosphenytoin.
- To establish optimal loading and maintenance dosing regimens for fosphenytoin in children.
- To identify factors influencing phenytoin pharmacokinetics in the pediatric population.
Main Methods:
- Retrospective population pharmacokinetic analysis using NONMEM v7.3.
- Inclusion of pediatric patients (<19 years) treated with fosphenytoin for seizures.
- Simulation to determine optimal dosing strategies.
Main Results:
- Analysis of 536 pediatric patients.
- Developed a two-compartment pharmacokinetic model incorporating fat-free mass, serum creatinine, and phenobarbital use.
- Simulations indicated a 20 mg/kg loading dose followed by 6 mg/kg every 8 hours as an effective regimen.
- Recommended dose reductions for patients with impaired renal function.
Conclusions:
- A 20 mg/kg loading dose and 6 mg/kg every 8-hour maintenance dose is a suitable empiric strategy for achieving therapeutic phenytoin concentrations.
- Fat-free mass is a key covariate for dosing.
- Concomitant phenobarbital use may increase phenytoin clearance, necessitating dose consideration.
- Fosphenytoin dose reduction is advised in pediatric patients with compromised kidney function.
Objective:
The purpose of this study is to describe the pharmacokinetics of phenytoin in pediatric patients receiving fosphenytoin.
Design:
Retrospective, population pharmacokinetic analysis.
Setting:
Emergency department or PICU of a large tertiary care children's hospital.
Patients:
Patients less than 19 years old who received fosphenytoin in the PICU or emergency center for treatment of seizures from January 2011 to June 2017 were included.
Interventions:
Population pharmacokinetic analysis was performed with NONMEM v7.3 (Icon Plc, Dublin, Ireland). Simulation was performed to determine optimal loading dose and maintenance dosing regimens.
Measurements And Main Results:
A total of 536 patients (55.4% male; median age, 3.4 yr [interquartile range, 0.92-8.5 yr]) met study criteria. Fosphenytoin was administered at median 15.1 mg/kg/dose (interquartile range, 6.3-20.7 mg/kg/dose). Mean serum concentrations of 17.5 ± 7.8 mg/L were at a median 4.2 hours (interquartile range, 2.5-7.8 hr) after a dose. A pharmacokinetic model with two compartments, allometrically scaled fat-free mass on all parameters, and serum creatinine and concomitant phenobarbital use on clearance had the best fit. Simulation demonstrated that a 20 mg/kg loading dose followed by 6 mg/kg/dose every 8 hours had the greatest percentage of concentrations in the 10-20 mg/L range, with reduced doses to achieve therapeutic in patients with reduced kidney function.
Conclusions:
A loading dose of 20 mg/kg followed by 6 mg/kg/dose every 8 hours based on fat-free mass is a reasonable empiric strategy for attainment and maintenance of therapeutic trough concentrations. Concomitant phenobarbital use may increase clearance of phenytoin and fosphenytoin dose reductions should occur in patients with reduced kidney function.
More Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
06:33Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
Related Concept Videos
Analysis of Population Pharmacokinetic Data
Conservation of Small Populations
What is Population Genetics?
Population Growth
What are Populations and Communities?
Pharmacokinetics in Pediatric Patients: Drug Excretion